Management of patients with Björk-Shiley prosthetic valves

There are three basic types of Björk-Shiley valve (figure) that may be encountered in British patients. The much publicised hazard of strut fracture is effectively confined to the convexo-concave valve so in advising and managing patients electively it is helpful to be able to identify these valves. To some extent the identity of the valve can be determined from its date of implantation, but valves can be distinguished with certainty by their serial numbers when these are available. Otherwise it should be possible to identify them by radiological appearances.

Earlier valves
The original valve with a Delrin disc was implanted in about 85 000 patients between 1969 and 1979.12 This was replaced with a pyrolitic carbon disc, known as a “spherical disc”, that had a 60° opening angle. About 180 000 of these valves were implanted up to 1987. The serial numbers carry the prefix ABP for aortic valves and MBRP, MBUP, and MBF for mitral valves, where the first two initials (AB or MB) denote site and Björk design and the last initial (P) identifies the spherical disc pattern. (The U and R refer to details of the relation of the sewing ring to the annulus.) The two struts, which are visible radiologically, can be seen to overlap when the valve is imaged en face (Fig 1A). By 1979 there were only three reports of the disc escaping, out of a total of 90 000 implants. These were probably related to damage to the struts at the time of implan tation.1 Long term follow up in a large series was free of mechanical failure.3

The convexo-concave valve
Between 1976 and 1986 the convexo-concave (CC) valve was implanted.4 In 1979 the new design was approved by the USA Food and Drugs Administration (FDA).5 It was introduced in an attempt to improve the flow characteristics across the valve and reduce the risk of thrombus formation. The new 60° convexo-concave valve was implanted in about 82 000 patients before being withdrawn in April 1985 by Shiley. Case reports of strut fractures6,7 include photographs of a consistent problem. The smaller strut had become detached from the annulus at the site of a weld and the disc escaped. In the meantime Shiley experimented with a 70° version of the same valve which unfortunately was even more prone to this problem. About one in eight of these valves was likely to fracture within seven years of implantation.7 It was never released in the United States but about 4000 were implanted elsewhere between 1980 and 1983.8 The codes for the CC valves are ABC, MBRC, MBUC, and MBC; again the final letter indicates the disc pattern and the numbers 60 or 70 denote the opening angle. The struts do not overlap when the valve is seen en face (Fig 1B). The valves particularly at risk are the 29 mm, 31 mm, and 33 mm mitral valves manufactured between February 1981 and June 1982. The overall risk of strut fracture is said to be 0.295% per annum.9 More detailed estimates have been made by size and postoperative year10 and are under 0.1% per annum in the low risk categories. These are likely to be underestimates because rapid deterioration or sudden death may well be attributed to other cardiac or non-cardiac causes and strut fracture will go undiagnosed.

The monostrut valve
The monostrut valve was designed to overcome the strut fracture problem and seems to have done so successfully. It was introduced on to the market in 1983 but has never had FDA approval and is not available in the United States. The metal ring with its retaining struts is milled from a single piece. It can readily be identified on a penetrated x ray. The serial numbers begin with the letters ABMS, MBMS, and MBRMS; MS denotes monostrut.

The future
While it is easy to be wise after the event, it is hard to draw any firm conclusions for the future from this experience. Cardiac surgery is now routine and commonplace and patients and their physicians have come to expect perfect results. But there are many things that can go wrong and with long life expectancy after valve replacement many years in which they can go wrong. The United Kingdom Heart Valve Registry provides a mechanism by which a pattern of sudden death in valve recipients can be detected early.10 Of course bench testing should be thorough before clinical use of a new device is contemplated and every care should be taken to do meticulous clinical follow up but because most patients who have heart valve replacements...
are expected to survive for more than 15 years" so sooner or later fair wear and tear will take its toll of mechanical devices performing 42 million cycles per year. The annual incidence of problems related to the mechanical valve itself is minute in comparison with the number of patients who die each year of endocarditis, valve thrombosis, embolism, anticoagulant related haemorrhage, and natural progression of disease in the heart and elsewhere. Virtually all mechanical valve recipients will die with an intact prosthesis. Without innovation we cannot make further progress and yet we know that it has now become extremely difficult for anyone to pioneer a new valve or even a small modification of an old one. If "the industry is so punished by the press and professional critics that innovation is stifled and the risk for failure becomes too great to continue" then we will see no further progress in valve design. This situation seems to be upon us in the USA.13

The more immediate problem is how should a clinician deal with patients who have these valves in place. The first obvious piece of advice is that in any patient with an artificial valve that deteriorates, first suspect the valve. If strut fracture has occurred the only hope is emergency reoperation so no time should be lost in referring the patient to the nearest cardiac surgical unit. Strut fracture can be diagnosed by screening alone.

The commoner problem is the large number of patients who remain well but are afraid. First of all the valve should be identified by serial number and if this is not available screening may be justified to identify spherical and monostatu valves which are not prone to this problem, so that the patient can be given this reassuring news without delay. Symptoms and clinical change must be dealt with on their merits but the individual can be strongly reassured about the theoretical risk of strut fracture in the future. For patients with a convexo-concave valve, while action may not be justified, reassurance must be a little more guarded because one in 30 of those with a mitral valve that is 29 mm or larger is at risk of death due to strut fracture. The alternative of electively replacing the valve carries a far worse risk. The risk of death with reoperation on the mitral valve was nearly 16% in 206 cases operated on in United Kingdom units in 1989 (70% confidence interval 13% to 19%), that is more than three times that of a first operation (J Cleland. United Kingdom Cardiac Surgical Register, personal communication). Reoperation doubles the risk in aortic valve replacement from just over 4% to nearly 9% (70% CI 6% to 12%). Of course it could be argued that these figures are those for clinically indicated reoperation including patients with catastrophic states such as endocarditis or sudden valve failure. Nevertheless, the difference between the risk of strut fracture and that of repeat valve surgery is sufficiently great that elective replacement of these valves for fear alone is unjustifiable.

And what is the legal position? Shiley have publicly indicated their willingness to meet claims from patients who have experienced strut fractures and they have settled directly to avoid protracted legal cases. Whether this is a generous and humane gesture or an economically sound strategy is open to interpretation but we all know that the law is a slow and bitter way of gaining compensation for medical injury. On the other hand Shiley will "vigorously defend" anxiety claims and believe that a "functioning valve is no basis for a claim".

I thank Mr J Cleland for supplying figures from the United Kingdom Cardiac Surgical Register and Mr Philip Ayers of Shiley for providing illustrations and technical data.

TOM TREASURE

St George's Hospital,
Blackshaw Road,
London SW17 0QT

Management of patients with Björk-Shiley prosthetic valves.

T Treasure

Br Heart J 1991 66: 333-334
doi: 10.1136/hrt.66.5.333

Updated information and services can be found at:
http://heart.bmj.com/content/66/5/333.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/